Scopus Biopharma Inc (SCPS)

The total asset value of Scopus Biopharma Inc (SCPS) stood at $ 8 Mln as on 31-Mar-23

The share price of Scopus Biopharma Inc (SCPS) is $0.05 (NASDAQ) as of 04-Dec-2023 15:58 EST. Scopus Biopharma Inc (SCPS) has given a return of -76.58% in the last 1 years.

Scopus Biopharma Inc (SCPS) has a market capitalisation of $ 2 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Scopus Biopharma Inc (SCPS) is 2.42 times as on 09-Jun-2023, a -0.05% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Scopus Biopharma Inc (SCPS) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Scopus Biopharma Inc (SCPS) and enter the required number of quantities and click on buy to purchase the shares of Scopus Biopharma Inc (SCPS).

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

The CEO & director of Mr. Robert J. Gibson. is Scopus Biopharma Inc (SCPS), and CFO & Sr. VP is Mr. Ira Scott Greenspan.

The promoters of Scopus Biopharma Inc (SCPS) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

No, TTM profit after tax of Scopus Biopharma Inc (SCPS) was $-5 Mln.